Camber Pharmaceuticals Launches Chlorpromazine Hydrochloride Injection in 25 mg/mL Single-Dose Vials

Camber Pharmaceuticals has introduced Chlorpromazine Hydrochloride Injection, USP to its product lineup. The medication is available in a concentration of 25 mg/mL and comes in 2 mL single-dose vials. This addition expands the company’s portfolio of injectable medications.

Chlorpromazine Hydrochloride Injection is commonly used for the management of various psychiatric disorders, including schizophrenia and manic episodes associated with bipolar disorder. It is also indicated for nausea and vomiting control, preoperative sedation, and acute intermittent porphyria treatment. Camber’s new offering aims to meet the needs of healthcare providers by providing an additional option for these therapeutic uses.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: June 19, 2025

Related posts:

DrugPatentWatch.com Article: Post-ANDA Success Hinges on Patent Analysis and Stakeholder Relations for Generics and Biosimilars. Study Links Heightened Brain Impulsivity to Overeating in Response to Unhealthy Food Stimuli FDA Advisory Panel Rejects Expanded Use of Pfizer’s Talzenna for Prostate Cancer as AI Gains Traction in Improving Clinical Trial Diversity Giles Platford Discusses Takeda’s Focus on Plasma-Derived Therapies and Supply Chain Strategies

Author

Mark Chiang